Neurophet Joins BIO USA Exploring Global Partnerships and Business Opportunities

04 Jun, 2024

Neurophet Joins BIO USA Exploring Global Partnerships and Business Opportunities

Neurophet, an AI solution company for brain disease, is set to participate in the annual BIO International Convention 2024 (BIO USA) from June 3 to 6 in San Diego, U.S. Neurophet aims to create business opportunities with global pharmaceutical companies by showcasing its AI brain image analysis technology, which significantly improves time and cost efficiency in drug development.

At BIO USA, Neurophet will highlight its Imaging CRO (Contract Research Organization) service, used in clinical trials for Alzheimer's disease treatment. This service analyzes medical images, including MRI and PET scans, and identifies biomarkers using "Neurophet AQUA" and "Neurophet SCALE PET" software, both of which have received 510(k) clearance from the US FDA.

Neurophet's imaging CRO service ensures image data quality and compliance, providing consistent and reliable analysis results. It enhances pharmaceutical and biotech companies' success rates in new drug development, covering the entire clinical trial process from patient group determination to efficacy analysis and side effect monitoring.

Neurophet recently signed an agreement with AriBio to support the global phase 3 clinical trial of AR1001, an oral Alzheimer's treatment. CEO Jake Junkil Been emphasized the growing trend of partnerships between pharmaceutical companies and AI firms, highlighting the potential of Neurophet's Imaging CRO service in Alzheimer's drug development.

Neurophet's brain image analysis technology has garnered significant interest at global exhibitions and business events. The company is committed to fostering meaningful partnerships with global pharmaceutical companies at BIO USA, the world's largest bio industry event, attended by pharmaceutical companies, bio companies, university research institutes, and investment firms.

Neurophet, founded in 2016 by CEO Jake Junkil Been and CTO Donghyeon Kim, specializes in AI-based solutions for brain disease diagnosis, treatment guides, and treatment devices. Its major products include brain MRI analysis software "Neurophet AQUA," brain PET image analysis software "Neurophet SCALE PET," and brain imaging treatment planning software "Neurophet tES/TMS LAB." Neurophet is dedicated to helping patients with brain diseases, leveraging neuroscience expertise and AI technology to pioneer innovative solutions for brain health.